Company intelligence / Profile preview

Sagittarius Bio

Thousand Oaks, California, United Statessagittarius.bio ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Sagittarius Bio is developing next-generation therapies that stimulate the immune system against immunological, inflammatory, and cancerous diseases. The company is in its early stages with a focus on innovative gene therapy platforms. No clinical results have been published as of May 2025.[1][3]

Therapeutic areas: OncologyImmunology
Modalities: Gene therapiesBiologicsSmall molecules (inferred from CEO’s expertise)[3]
Industry: Biotech

Beyond the preview

Go deeper on Sagittarius Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sagittarius Bio.

Explore the full profile